Business description

Aerogen is the world’s leading medical device company specialising in the design, manufacture & commercialisation of aerosol drug delivery systems. Our patented vibrating mesh technology turns liquid medication into a fine particle mist, gently & effectively delivering drugs to the lungs of critically ill patients of all ages. Our innovative products - Aerogen® Solo and Aerogen® Ultra, significantly improve aerosol drug delivery resulting in better patient care throughout the Hospital. Founded in Galway, Ireland in 1997, we have grown to become the global leader in high performance aerosol drug delivery & have partnered our technology with the leading mechanical ventilation companies.

Products and services

Our patented palladium vibrating mesh technology lies at the heart of our category leading aerosol drug delivery systems, and has transformed the treatment of respiratory patients throughout the world. This technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of patients. Innovative products such as Aerogen Ultra and Aerogen Solo, which were developed using this technology, offer improved treatment for patients. These products work for the benefit of patients by delivering 6% greater lung deposition when compared to jet nebulisers. This versatile technology can be used throughout the hospital setting including ICU, HDU, ED, Wards, Neonate and Paediatric departments. In achieving these technological breakthroughs Aerogen has hit many landmark milestones along the way, including developing the world’s first silent nebuliser (Aerogen Solo).

Value proposition

Offering superior clinical performance and improving treatment of respiratory patients, is at the forefront of Aerogen’s philosophy. This commitment has led to over four million patients, in over 75 countries benefiting from these innovative technologies by receiving more effective and efficient treatment. The superior performance of our Aerosol Drug Delivery systems helps reduce the number of admissions of patients at ED departments due to the effective technology delivering 6 times the medication to patient’s lungs than traditional jet nebulizers, meaning patients receive more than twice the medication in half the time, leading to quicker recovery times and lower admission rates. All of this combined means patients’ length of stay in hospital and related costs are significantly reduced.

Standards and certificates

• ISO:13485:2012, CE Mark, 510K Approved 2016 European Entrepreneur of the Year – European Business Awards 2013, 2015, 2016, 2017 and 2018 Zenith Award for Respiratory Care Excellence – American Association of Respiratory Care 2014 Irish Exporter of the Year (Irish Exporters Association – IEA) 2013 Medical Technology Company of the Year (Irish Medical Devices Association , IDA Ireland, Enterprise Ireland) 2011 Silver IMDA Excellence (Irish Medical Devices Association) 2011 Finalist in Engineers Excellence Awards (Irish Engineering Awards)

Key partners

contact companycontact company